Share Price, page-11987

Maybe to maximise sale value due to possible impending cessation of the PRV scheme.Ipsen sold a voucher for US$158 million in August, so its possible Neuren could receive USD$50+ million from a PRV sale. This plus USD$50 million milestone payment = AUD$147 million, would put Neuren in a position to fully self fund both 2 Phase 3 trials and build Stateside infrastructure for commercialisation of 2591.

Thinking about Neuren going it alone, I don't envisage any issues slowing down rollout based on Neuren's size or inexperience. Telix Pharmaceuticals went hard early and hired experienced individuals to enable an incredibly successful rollout of their debut diagnostic Illucix, they contracted Cardinal to manage distribution, and continue to spend on R&D and infrastructure with nary a thought for the bottom line in the short term. All this in 7 years from a small office with a few filing cabinets in North Melbourne. The US is a very dynamic place to do business, setting up shop there can be done expeditiously with a vast talent pool of experienced pharmaceutical industry individuals to choose from.

TBH I'm looking for a quick resolution to the question of whether Neuren will be taken over, hopefully within the next year. But it's interesting that the vice president of translational research Rachel Groth only started with Neuren in February 2024. Not sure what to read into this development except Neuren is carrying on business as usual with a long term approach but cognisant that an offer could be made any time and preparing for such an event, running on 2 tracks as it were. The only thing I'd say about Rachel Groth's appointment is it appears Neuren isn't showing any hesitation or restriction in progressing development plans for 2591, the circumstances of which could bode well for a prospective suitor (not wanting to re-visit contractual interpretations).